A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Trial Profile

A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Heterotopic ossification
  • Focus Therapeutic Use
  • Sponsors Clementia Pharmaceuticals
  • Most Recent Events

    • 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top